The AgResults Brucellosis Vaccine Prize is a US $30 million global competition, which invites animal health innovators (‘Solvers’) to submit their proposals for – and ultimately develop – a suitable vaccine that is efficacious, safe and viable for use against Brucella melitensis a pathogen causing Brucellosis that particularly affects smallholder farmers in the developing world. The competition is funded by AgResults, a collaborative initiative between the governments of Australia, Canada, the United Kingdom and the United States as well as the Bill & Melinda Gates Foundation, in an effort to find innovative solutions from the private sector to seemingly intractable development challenges. The competition, which could last up to ten years, will be managed and implemented by the Global Alliance for Livestock Veterinary Medicines (GALVmed).
Animal health, biotech and vaccine companies and other organisations are invited to submit their proposals via the Brucellosis Vaccine Prize Competition website.
Current vaccines are not ideal for use in developing countries, as they do not provide protection across different species of animal hosts, are unsafe for use in pregnant animals, can harm humans, and have variable efficacy. A new vaccine that addresses these shortcomings would deliver lasting benefits to livestock health and improve smallholder farmer livelihoods.
This is a multi-disciplinary collaboration between GALVmed, the Malawi-based Centre for Tick and Tick-Borne Diseases and Arecor Ltd, a UK biotech company that develops novel formulations for the human health medical sector.
This partnership will provide a unique opportunity to translate British technology and expertise from the human health sector into livestock disease control in the developing world context. The programme focuses, on East Coast Fever, which kills over a million cattle per year and has a devastating effect on small-holder cattle production in East, Central and Southern Africa.
An effective vaccine, ECF-ITM, currently exists for the disease but it has a number of important drawbacks that affect its use in the field. This project will trial the use of novel formulations as a replacement for the ECF-ITM vaccine diluent. Success in the project will deliver important ECF-ITM vaccine product enhancements, notably vaccine stability. This will afford far greater mobility and flexibility to ECF vaccinators resulting in many more cattle being able to be effectively immunised.
A programme led by the Chinese Harbin Veterinary Research Institute. Contagious Bovine Pleuropneumonia is a disease of cattle that continues to afflict substantial losses in Africa, but which has been eradicated in many other parts of the world. In China the disease was eradicated following the use of the BEN-1 vaccine. Under this programme the Chinese developed BEN-1 vaccine is being evaluated for safety and efficacy in African conditions.
A two phase programme of work addressing the lack of disease control tools available to small-scale livestock producers in sub-Saharan Africa. Animal African Trypanosomosis is a parasitic disease that is often fatal to cows, sheep and goats in Africa – causing serious economic losses in African livestock.
The bulk of this work focuses on developing a new generation of therapeutic and prophylactic drugs to overcome issues with developing resistance in the parasite. Work on a vaccine candidate in phase 1 was discontinued following lack of efficacy. The programme will deliver the first practical field diagnostic test and is additionally developing regulatory quality control capabilities in sub-Saharan Africa to combat the burgeoning supply of sub-standard and counterfeit trypanocidal drugs. These sub-standard and counterfeit drugs contribute significantly to resistance development.
Many African countries have their own national laboratories for the production and supply of veterinary vaccines. This programme improved the technical capabilities of eight national laboratories in the production of four key livestock vaccines. Through the provision of improved equipment and associated training in systems and processes a substantially enhanced output in terms of quality and volume was achieved.
A substantial and multi-faceted programme of work separated into two workstreams. The product development workstream focuses on developing 9 to 11 new products (primarily veterinary vaccines but also pharmaceuticals and diagnostics) and various product improvements (such as heat tolerance, production cost reductions, formulations for easy applications etc.).
The market development workstream focuses on developing sustainable access to these products, with which is currently centred around Newcastle Disease and East Coast Fever vaccines, as products are becoming available in sustainable quantities. In direct support of these product and market development elements are a wide range of policy and advocacy issues, for example, facilitating a harmonised veterinary vaccination framework in the East Africa region.